pmxstudio.ai is open for projects.
The studio is now taking on population PK, exposure-response, MIDD and submission-package work, each on a fixed price and a fixed timeline. If you have a study readout on the horizon, we would be glad to scope it.
Company updates, new agent releases, and short notes on the regulatory and scientific developments that shape our work.
The studio is now taking on population PK, exposure-response, MIDD and submission-package work, each on a fixed price and a fixed timeline. If you have a study readout on the horizon, we would be glad to scope it.
The FDA's Project Optimus has moved dose optimisation from a late-stage afterthought to an early-development expectation. For many programmes that means an exposure-response analysis built while Phase 1 and 2 data are still arriving, rather than after.
It is a clear example of where a fast, well-scoped modelling package earns its place: the analysis has to keep pace with the trial, not trail it.
A pharmacometric analysis is a sequence of distinct tasks: assembling the dataset, drafting control streams, running diagnostics, keeping the run record, writing the report. Each one rewards a different kind of automation.
So instead of one general-purpose tool, we build a specialist agent for each step, every one under the review of a senior pharmacometrician. It is the main reason a full analysis runs in weeks rather than months.